PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTCT Rule 144 notice reporting proposed and recent transactions in Common Stock. The filing shows two restricted stock vesting events of 4,384 shares on 12/01/2025 and 5,616 shares on 12/29/2025. It also discloses three market sales by Matthew Klein during the prior three months: 7,371 shares for $511,227.50 on 02/18/2026, 2,662 shares for $170,572.44 on 03/12/2026, and 2,850 shares for $202,171.31 on 04/21/2026.
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sale transaction in company stock. On May 8, 2026, he exercised stock options to acquire a total of 3,540 shares of common stock at an exercise price of $46.54 per share.
That same day, he executed open-market sales totaling 3,540 shares at prices ranging from approximately $78.00 to $79.31 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, he directly holds 105,212 shares of PTC Therapeutics common stock.
PTCT affiliate submitted a Form 144 notice to sell 3,540 shares of Common Stock. The filing lists an option granted on 01/03/2025 and a planned sale date of 05/08/2026. The filing also shows three recent dispositions by Mark Boulding totaling 8,097 shares sold on 02/17/2026, 02/19/2026, and 04/06/2026, and reports 82,949,338 shares outstanding as of 05/08/2026.
PTC Therapeutics reports Q1 2026 results showing solid product growth but a small loss. Total revenues were $272.6 million, down from $1.18 billion a year earlier when a large Novartis upfront payment boosted collaboration revenue. Net product revenue grew to $225.6 million, led by Sephience for PKU and DMD therapies Translarna and Emflaza, while royalty revenue from Evrysdi and other partnered products reached $46.8 million. The quarter showed an operating profit of $45.0 million, but after $49.0 million of net interest expense, mainly from the royalty financing and convertible notes, PTC recorded a net loss of $2.8 million. Cash, cash equivalents and marketable securities totaled about $1.89 billion, and management believes this, together with product sales and Novartis milestones, will fund operations for at least twelve months. The filing also highlights progress across rare‑disease programs, including global launches of Sephience, the Phase 3 votoplam program for Huntington’s disease now led by Novartis, and ongoing regulatory work on vatiquinone for Friedreich’s ataxia.
PTC Therapeutics, Inc. reported first quarter 2026 total revenue of $272.6 million, including $225.6 million in net product revenue and $46.8 million in royalty revenue. Management said this strong start supports raising full-year 2026 product revenue guidance.
Global Sephience sepiapterin revenue reached $125 million in the quarter, reflecting 36% quarter-over-quarter growth. The company reported a small net loss of $2.8 million, or $(0.03) per basic and diluted share, compared with a large prior-year profit that included substantial collaboration revenue.
PTC highlighted positive topline results from a 24‑month interim analysis of the PIVOT‑HD votoplam extension study and continued work on the global Phase 3 INVEST‑HD study. An open-label vatiquinone registration study is planned to start in Q3 2026. Cash, cash equivalents and marketable securities were $1.89 billion as of March 31, 2026.
PTC Therapeutics Inc. Vanguard Capital Management reports beneficial ownership of 4,284,448 shares of Common Stock, representing 5.17% of the class as reported on 03/31/2026. The filing states Vanguard has sole dispositive power over 4,284,448 shares and sole voting power over 608,192 shares. The filing explains these holdings include securities held for Vanguard funds and client accounts managed by affiliated divisions.
Vanguard Portfolio Management reports beneficial ownership of 4,871,329 shares of PTC Therapeutics common stock, representing 5.88% of the class as of 03/31/2026. The filing shows sole voting power of 66,735 shares and sole dispositive power over 4,871,329 shares. The statement clarifies holdings reflect assets managed across Vanguard affiliates and funds.
PTC Therapeutics reported positive 24‑month interim results from its PIVOT‑HD long‑term extension study of votoplam in Huntington’s disease. Stage 2 patients showed dose‑dependent slowing of disease progression on the cUHDRS scale versus a matched natural history cohort, with 52% slowing at the 10 mg dose and 28% at 5 mg.
Safety after 24 months remained consistent with the previously favorable profile, with no treatment‑related increases in neurofilament light chain and mean levels staying below baseline, unlike typical HD progression. Novartis has initiated the global placebo‑controlled Phase 3 INVEST‑HD study of votoplam in approximately 770 early‑stage HD patients, further advancing the program.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 2,850 shares of common stock at $70.91 per share. According to the filing, the shares were sold under an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 6,500 RSUs from a prior 26,000-RSU grant. After this transaction, Klein directly holds 394,070 shares, indicating a small, tax-driven reduction in his overall stake.
PTCT filed a Form 144 reporting planned or recent sales of Common Stock. The filing shows 2,850 shares tied to restricted stock vesting with an issuer compensation designation dated 04/20/2026. It also lists two dispositions in the past three months: 7,371 shares for $511,227.50 and 2,662 shares for $170,572.44. Shares outstanding are listed as 82,774,730 as of 04/21/2026.